Shanghai Fosun Pharmaceutical Group Co Ltd (600196) - Total Assets
Based on the latest financial reports, Shanghai Fosun Pharmaceutical Group Co Ltd (600196) holds total assets worth CN¥120.47 Billion CNY (≈ $17.63 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Shanghai Fosun Pharmaceutical Group Co L for net asset value and shareholders' equity analysis.
Shanghai Fosun Pharmaceutical Group Co Ltd - Total Assets Trend (1995–2025)
This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data.
Shanghai Fosun Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Fosun Pharmaceutical Group Co Ltd's total assets of CN¥120.47 Billion consist of 28.1% current assets and 71.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.8% |
| Accounts Receivable | CN¥11.28 Billion | 9.4% |
| Inventory | CN¥6.25 Billion | 5.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥20.53 Billion | 17.0% |
| Goodwill | CN¥10.81 Billion | 9.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Fosun Pharmaceutical Group Co L (600196) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Fosun Pharmaceutical Group Co Ltd's current assets represent 28.1% of total assets in 2025, a decrease from 96.9% in 1995.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2025, up from 6.7% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 17.0% of total assets.
Shanghai Fosun Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Shanghai Fosun Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Shanghai Fosun Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 0.92 | 1.05 |
| Quick Ratio | 0.76 | 0.73 | 0.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-2.60 Billion | CN¥-2.96 Billion | CN¥1.42 Billion |
Shanghai Fosun Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Fosun Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | CN¥120.47 Billion |
| Market Capitalization | $7.72 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Fosun Pharmaceutical Group Co Ltd's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shanghai Fosun Pharmaceutical Group Co Ltd's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shanghai Fosun Pharmaceutical Group Co Ltd (1995–2025)
The table below shows the annual total assets of Shanghai Fosun Pharmaceutical Group Co Ltd from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥120.47 Billion ≈ $17.63 Billion |
+2.56% |
| 2024-12-31 | CN¥117.46 Billion ≈ $17.19 Billion |
+3.52% |
| 2023-12-31 | CN¥113.47 Billion ≈ $16.60 Billion |
+5.88% |
| 2022-12-31 | CN¥107.16 Billion ≈ $15.68 Billion |
+14.87% |
| 2021-12-31 | CN¥93.29 Billion ≈ $13.65 Billion |
+11.48% |
| 2020-12-31 | CN¥83.69 Billion ≈ $12.25 Billion |
+9.94% |
| 2019-12-31 | CN¥76.12 Billion ≈ $11.14 Billion |
+7.89% |
| 2018-12-31 | CN¥70.55 Billion ≈ $10.32 Billion |
+13.85% |
| 2017-12-31 | CN¥61.97 Billion ≈ $9.07 Billion |
+41.59% |
| 2016-12-31 | CN¥43.77 Billion ≈ $6.40 Billion |
+14.57% |
| 2015-12-31 | CN¥38.20 Billion ≈ $5.59 Billion |
+8.11% |
| 2014-12-31 | CN¥35.34 Billion ≈ $5.17 Billion |
+19.88% |
| 2013-12-31 | CN¥29.48 Billion ≈ $4.31 Billion |
+15.56% |
| 2012-12-31 | CN¥25.51 Billion ≈ $3.73 Billion |
+14.43% |
| 2011-12-31 | CN¥22.29 Billion ≈ $3.26 Billion |
+32.52% |
| 2010-12-31 | CN¥16.82 Billion ≈ $2.46 Billion |
+45.92% |
| 2009-12-31 | CN¥11.53 Billion ≈ $1.69 Billion |
+52.90% |
| 2008-12-31 | CN¥7.54 Billion ≈ $1.10 Billion |
+1.40% |
| 2007-12-31 | CN¥7.43 Billion ≈ $1.09 Billion |
+12.08% |
| 2006-12-31 | CN¥6.63 Billion ≈ $970.75 Million |
+17.03% |
| 2005-12-31 | CN¥5.67 Billion ≈ $829.51 Million |
+9.64% |
| 2004-12-31 | CN¥5.17 Billion ≈ $756.61 Million |
+22.56% |
| 2003-12-31 | CN¥4.22 Billion ≈ $617.35 Million |
+34.38% |
| 2002-12-31 | CN¥3.14 Billion ≈ $459.42 Million |
+42.23% |
| 2001-12-31 | CN¥2.21 Billion ≈ $323.00 Million |
+40.50% |
| 2000-12-31 | CN¥1.57 Billion ≈ $229.90 Million |
+83.06% |
| 1999-12-31 | CN¥858.23 Million ≈ $125.59 Million |
+32.62% |
| 1998-12-31 | CN¥647.14 Million ≈ $94.70 Million |
+125.38% |
| 1997-12-31 | CN¥287.13 Million ≈ $42.02 Million |
+158.00% |
| 1996-12-31 | CN¥111.29 Million ≈ $16.29 Million |
+4.31% |
| 1995-12-31 | CN¥106.70 Million ≈ $15.61 Million |
-- |
About Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more